Improving the Intracellular Drug Concentration in
Lung Cancer Treatment through the Codelivery of Doxorubicin and miR-519c
Mediated by Porous PLGA Microparticle
Di Wu
Chenhui Wang
Jiebing Yang
Hao Wang
Haobo Han
Aijun Zhang
Yan Yang
Quanshun Li
10.1021/acs.molpharmaceut.6b00702.s001
https://acs.figshare.com/articles/journal_contribution/Improving_the_Intracellular_Drug_Concentration_in_Lung_Cancer_Treatment_through_the_Codelivery_of_Doxorubicin_and_miR-519c_Mediated_by_Porous_PLGA_Microparticle/3993720
Porous
PLGA microparticle for the coencapsulation of doxorubicin and miR-519c
was successfully constructed through the water–oil–water
emulsion solvent evaporation method, using ammonium bicarbonate as
a porogen. It has been characterized with high porous surface, adaptive
aerodynamic diameter (<10 μm), favorable drug loading, and
sustained release profile. The release supernatant exhibited a higher
inhibition of cell proliferation than those from porous PLGA microparticles
harboring a single component (doxorubicin or miR-519c), attributing
to the enhanced induction of cell apoptosis and cell cycle arrest
at S phase. Finally, the improved intracellular concentration of doxorubicin
was elucidated by flow cytometry and liquid chromatography with tandem
mass spectrometry, owing to the knockdown of drug transporter ABCG2
by miR-519c. Overall, the porous PLGA microparticle combining chemotherapy
and gene therapy could facilitate the antitumor efficacy and reduce
the side effects, and thus, it is potential to be used as a sustained
release system for lung cancer treatment via pulmonary administration.
2016-09-29 00:00:00
tandem mass spectrometry
release
cell cycle arrest
drug transporter ABCG 2
lung cancer treatment
Lung Cancer Treatment
Porous PLGA Microparticle Porous PLGA microparticle
doxorubicin
miR -519c
Intracellular Drug Concentration
miR -519c Mediated